+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Mild Traumatic Brain Injury Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896147
  • Report
  • January 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence
UP TO OFF
until Mar 31st 2020
1 of 4

FEATURED COMPANIES

  • Grace Laboratories LLC.
  • Medtronic PLC
  • Vasopharm GmbH
  • MORE
Market Overview

Global Mild Traumatic Brain Injury Treatment market is expected to witness a CAGR of 3.8% during the forecast period. Certain factors that are driving the market growth include Increasing Incidence Of Mild Traumatic Brain Injuries, and Ongoing Product Development and Approval.

Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of epidemiology is an important and potential bias in studies should be explored. Traumatic brain injury (TBI) is a complex injury comprising a spectrum from mild TBI (MTBI) with low risk of persistent disability, to the most severe TBI with devastating brain damage. However, MTBI constitutes 80–90 % of all TBI.

Scope of the Report

A patient with mild traumatic brain injury is a person who has had a traumatically induced physiological disruption of brain function. It has been recognized that patients with a mild traumatic brain injury can exhibit persistent emotional, cognitive, behavioral, and physical symptoms, alone or in combination, which may produce a functional disability.

Key Market Trends

Hospital is Expected to Hold Significant Market Share in the End User Segment

Therapy for MTBI usually begins in the hospital and continues at an inpatient rehabilitation unit, a residential treatment facility or outpatient services. The type and duration of rehabilitation are different for everyone, depending on the severity of the brain injury and what part of the brain was injured. People with mild traumatic brain injuries may also have other injuries that need to be addressed. Additional treatments in the emergency room or intensive care unit of a hospital generally focus on minimizing secondary damage due to inflammation, bleeding or reduced oxygen supply to the brain.

North America Dominates the Market and Expected to do Same in the Forecast Period

Traumatic brain injury (TBI), also known as acquired brain injury, head injury, or brain injury, causes substantial disability and mortality in the American population. It occurs when a sudden trauma damages the brain and disrupts normal brain function. TBI often has profound physical, psychological, cognitive, emotional, and social effects on the lives of American people. Mild TBI appears to be vastly under-diagnosed in the setting of systemic trauma, even in trauma centers. According to the CDC, there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the United States in 2015. Hence, the rising prevalence of MTBI is expected to drive the overall growth of the market across the entire region.

Competitive Landscape

The global Mild Traumatic Brain Injury Treatment market is highly competitive and consists of a number of major players. Companies like Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB , Stemedica Cell Technologies Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others, hold the substantial market share in the Mild Traumatic Brain Injury Treatment market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Grace Laboratories LLC.
  • Medtronic PLC
  • Vasopharm GmbH
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence Of Mild Traumatic Brain Injuries
4.2.2 Ongoing Product Development And Approval
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 Shortage Of Trained Professionals
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment
5.1.1 Drugs
5.1.2 Surgery
5.2 End Users
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Grace Laboratories LLC.
6.1.2 Integra LifeSciences Corporation
6.1.3 Medtronic PLC
6.1.4 Neuren Pharmaceuticals Ltd.
6.1.5 NeuroVive Pharmaceutical AB
6.1.6 Stemedica Cell Technologies Inc.
6.1.7 TEVA Pharmaceutical Industries Ltd.
6.1.8 Vasopharm GmbH

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Grace Laboratories LLC.
  • Integra LifeSciences Corporation
  • Medtronic PLC
  • Neuren Pharmaceuticals Ltd.
  • NeuroVive Pharmaceutical AB
  • Stemedica Cell Technologies Inc.
  • TEVA Pharmaceutical Industries Ltd.
  • Vasopharm GmbH
Note: Product cover images may vary from those shown
Adroll
adroll